Stem cell transplantation in Hodgkin lymphoma

Expert Review of Anticancer Therapy

Volumn 7, Issue 3, 2007, Pages 297-306

  Murphy, Felicity ^a   Sirohi, Bhawna ^a   Cunningham, David ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Allogeneic transplant; Autologous transplant; Hodgkin lymphoma; Prognostic factors; Refractory; Relapsed; Salvage chemotherapy

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GYRASE INHIBITOR; IFOSFAMIDE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; NAVELBINE; PREDNISOLONE; PROCARBAZINE; THIOTEPA; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANXIETY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER PALLIATIVE THERAPY; CANCER RELAPSE; CLINICAL TRIAL; DEPRESSION; DRUG MEGADOSE; HEALTH SURVEY; HEART DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; INFECTION; INFERTILITY; LUNG TOXICITY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASIA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PNEUMONIA; PROGNOSIS; REVIEW; SECOND CANCER; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

AGE FACTORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; INCIDENCE; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33947654400     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.3.297     Document Type: Review

References (80)

1. Cartwright R, Brincker H, Carli P, et al. The rise in incidence of lymphomas in Europe, 1985-1992. Eur. J. Cancer 35, 627-633 (1999).
2. Meyer R, Ambinder R, Stroobants S. Hodgkins lymphorna: evolving concepts with implications for practice. Hematology Am. Soc. Hematol, Educ. Program 184-202 (2004).
3. Canellos GP, Anderson JR, Propert KJ et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N. EngL J. Med. 327, 1478-1483 (1992).
4. Diehl V, Franklin J, Pfreundschuh M et al. German Hodgkin's Lymphoma Study Group standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N. Engl. J. Med. 348, 2386-2395 (2003).
5. Oza AM, Ganesan TS, Leahy M et al. Patterns of survival in patients with Hodgkin's disease: long follow up in a single centre. Ann. Oncol. 4, 385-492 (1993).
6. Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 96, 1280-1286 (2000).
7. Appelbaum FR, Herzig GP, Ziegler JL et al. Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood 52, 85-95 (1978).
8. Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous marrow transplantation after failure of conventional chemotherapy in adults with 1 intermediate-grade or high-grade non-Hodgkin's lymphoma. N. Engl. J. Med. 316, 1493-1498 (1987).
9. Carella AM, Santini G, Santoro A et al. Massive chemotherapy with non-frozen autologous bone marrow transplantation in 13 cases of refractory Hodgkin's disease. Eur. J. Clin. Oncol, 21, 607-613 (1985).
10. Philip T, Dumont J, Teillet F et al. High dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin's disease. Br. J. Cancer 53, 737-742 (1986).
11. Jagannath S, Dicke KA, Armitage JO et al. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann. Intern. Med. 104, 163-168 (1986).
12. Copelan EA. Hematopoietic stem-cell transplantation. N. Engl. J Med. 354, 1813-1826 (2006).
13. Anderson JE, Litzow MR, Appelbaum FR et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin. Oncol 11, 2342-2350 (1993).
14. Akpek G, Ambinder RF, Piantadosi S et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J. Clin. Oncol. 19, 4314-4321 (2001).
15. Porter DL, Connors JM, Van Deerlin VM et al. Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J. Clin. Oncol. 17, 1234-1243 (1999).
16. Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347, 353-357 (1996).
17. Yung L, Linch D. Hodgkin's lymphoma. Lancet 361, 943-951 (2003).
18. Bonadonna G, Santoro A, Gianni AM et al. Primary and salvage chemotherapy in advanced Hodgkies disease: the Milan Cancer Institute experience. Ann. Oncol. 2(Suppl. 1), 9-16 (1991).
19. Viviano S, Bonfante V, Di Nicola S et al. Long-term results of high-dose chemotherapy (HDCT) supported by hematopoietic circulating (ASCT) or bone marrow (BMT) stem cell autografting as first salvage treatment far refractory or relapsed Hodgkin's lymphoma. ASCO Annual Meeting 2006, Atlanta, GA, USA (2006) (General Poster Session 7567).
20. Sweetenham JW, Taghipou G, Linch DC, Goldstone AH. Thirty percent of adult patients with primary refractory Hodgkin's disease are progressive free at 5 years after high-dose therapy and autologous stem cell transplantation: data from 290 patients reported to the EBMT. Blood 8(Suppl. 1), A486 (1996).
21. Longo D, Duffey P, Young R. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J. Clin. Oncol. 10, 210-218 (1992).
22. Bonfante V, Santoro A, Viviani S. Outcome of patients with Hodgkin's disease failing after primary MOPP/ABVD. J. Clin. Oncol. 15, 528-534 (1997).
23. Josting A, Franklin J, May M et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin lymphoma registered in the database of the German Hodgkin Lymphoma Study Group (GHSG). J. Clin. Oncol. 20, 221-230 (2002).
24. Bartlett N. Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy. Hematology Am. Soc. Hematol. Educ. Program 245-251 (2005).
25. Yahalom J, Gulati S. Autologous bone marrow transplantation for refractory or relapsed Hodgkin's disease: the Memorial Sloan-Kettering Cancer Center experience using high-dose chemotherapy with or without hyperfractionated accelerated total lymphoid irradiation. Ann. Oncol. 2(Suppl. 2), 67-71 (1991).
26. Svoboda J, Andreadis C, Elstrom. R et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant. 38, 211-216 (2006).
27. Moskowitz CH, Glassman JR, Wuest D et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin. Cancer Res. 4, 311-316 (1998).
28. Rodriguez J, Rodriguez MA, Fayad L et al. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood 11, 3632-3636 (1999).
29. Pfieundschuh MG, Rueffer U, Lathan B et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. J. Clin. Oncol. 12, 580-586 (1994).
30. Colwill R, Crump M, Couture F et al. Mini-BEAM as salvage therapy fbr relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J. Clin. Oncol. 13, 396-402 (1995).
31. Moskowitz CH, Nimer SD, Zelenetz AD et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin's disease: analysis by intent to treat and development of a prognostic model. Blood 97, 616-623 (2001).
32. Josting A, Rudolph C, Reiser M et al. Time-intensified dexamethasone/ cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed or refractory Hodgkin's diseases. Ann. Oncol. 10, 1628-1635 (2002).
33. Aparicio J, Segura A, Garcera S. et al. ESHAP is an active regimen for relapsing Hodgkin's disease. Ann. Oncol. 10, 593-595 (1999).
34. Baetz T, Belch A, Couban S et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann. Oncol. 14, 1762-1767 (2003).
35. Ng M, Waters J, Cunningham D et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br. J. Cancer 92, 1352-1357 (2005).
36. Gutierrez-Delgado F, Holmberg L, Hooper H et al. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiopeta compared to a radiation-based regimen. Bone Marrow Transplant. 32, 279-285 (2003).
37. Sureda A, Arranz R, Iriondo A et al. Autologous stem-cell transplantation for Hodgkids disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin. Oncol. 19, 1395-1404 (2001).
38. Chen CI, Abraham R, Tsang R et al. Radiation-associated pneumonitis following autologous stem cell transplant: predictive factors, disease characteristics and treatment outcomes. Bone Marrow Transplant. 27, 117-182 (2001).
39. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 341, 1051-1054 (1993).
40. Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haernopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 359, 2065-2071 (2002).
41. Schmitz N, Haverkamp H, Josting A et al. Long term follow up in relapsed Hodgkin's disease (HD): updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoetic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT). ASCO Annual Meeting 2005 Orlando, Florida, USA (2005) (23 Abstract 6508a).
42. Hasenclever D, Diehl V, Armitage JO et al A prognostic score for advanced Hodgkins disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N. Engl. J. Med. 339, 1506-1514 (1998).
43. Bierman PJ, Lynch JC, Bociek RG et al. The International Prognostic Factors Project Score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann. Oncol. 13, 1370-1377 (2002).
44. Federico M, Bellei M, Brice P et al. High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkins lymphoma responding to front-line therapy. J. Clin. Oncol. 21, 2320-2325 (2003).
45. Saghatchian M, Djeridane M, Escoffre-Barbe M et al. Very high risk Hodgkin's disease (HD): ABVD 4 cycles plus BEAM followed by autologous stem cell transplantation (ASCT) and radiotherapy (RT) versus intensive chemotherapy (3 cycles) (INT-CT) and RT. Four-year results ofthe GOELAMS H97-GM multicentric randomised trial (abstract). Proc. Am. Soc. Clin. Oncol. 21, A263 (2002).
46. Moskowitz CH, Kewalramani T, Nimer S, Gonzalez M, Zelenetz A, Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br. J. Haematol. 124, 645-652 (2004).
47. Klimm B, Schnell R, Diehl V, Engert A. Current treatment and immunotherapy of Hodgkies lymphoma. Haematologica 90, 1680-1692 (2005).
48. Josting A, Rudolph C, Mapara M et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann. Oncol. 16, 116-123 (2005).
49. Glossman JP, Josting A, Pfistner B, Paulus U, Engert A. A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2). Ann. Haematol. 81, 424-429 (2002).
50. Paltiel O, Rubinstein C, Or R et at Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma. Bone Marrow Transplant. 31, 565-569 (2003).
51. Devizzi L, Santoro A, Bonfante V et al. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease. Ann. Oncol. 5, 817-820 (1994).
52. Little R, Wittes RE, Longo DL, Wilson WH. Vinblastine for recurrent Hodgkin's disease following autolgous bone marrow transplant. J Clin. Oncol. 16, 584-588 (1998).
53. Venkatesh H, Di Bella N, Flynn TP, Vellek MJ, Boehm KA, Asmar L. Results of a Phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma. Clin. Lyphoma. 5, 110-115 (2004).
54. Lin TS, Avalos BR, Penza SL, Marcucci G, Elder PJ, Copelan EA. Second autologous stem cell transplant for multiple relapsed Hodgkin's disease. Bone Marrow Transplant. 29, 763-767 (2002).
55. Vandenberghe E, Pearce R, Taghipor G, Fouillard L, Goldstone A. Role of a second transplant in the management of poor-prognosis lymphoma: a report from the European Blood and Bone Marrow Registry. J. Clin. Oncol. 15, 1595-1600 (1997).
56. Jones RJ, Ambinder RF, Piantadosi S, Santos GW, Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77, 649-653 (1991).
57. Gajewski JL, Phillips GL, Sobocinski KA et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J. Clin. Oncol. 14, 572-578 (1996).
58. Milpied N, Fielding AK, Pearce RM et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J. Clin. Oncol, 14, 1291-1296 (1996).
59. Carella AM, Champlin R, Slavin S, McSweeney P, Storb R. Mini-allografts: ongoing trials in humans. Bone Marrow Transplant. 25, 345-350 (2000).
60. Sureda A, Robinson S, Ruiz de Elvira C. Non-myeloablative allogeneic stem cell transplantation reduces transplant related mortality in comparison with conventional alloegneic transplantation in relapsed or refractory Hodgkin's disease: results of the European Group for Blood and Marrow Transplantation. Blood 102(Suppl. 1), 1461 (2003) (Abstract 692).
61. Baron F, Storb R. Current roles for allogeneic hematopoietic cell transplantation following nonmyeloablative or reduced-intensity conditioning. Clin. Adv. Hematol, Oncol. 3, 799-819 (2005).
62. Peggs KS, Hunter A, Chopra R et al. Clinical evidence of graft-versus- Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 365, 1934-1941 (2005).
63. Carella AM, Cavaliere M, Lerma E et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic periperhal-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin. Oncol, 18, 3918-3924(2000)
64. Josting A, Nogova L, Franklin J et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin. Oncol. 23, 1522-1529 (2005).
65. Poen JC, Hoppe RT, Horning SJ. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival. Int. J Radiat. Oncol. Biol Phys. 36, 3-12 (1996).
66. Wendland MM, Asch JD, Pulsipher MA, Thomson JW, Shrieve DC, Gaffney DK. The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease. Am J. Clin. Oncol. 29(2), 189-195 (2006).
67. Yahalom J. Transformation in the use of radiation therapy of Hodgkin lymphoma: new concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT). Eur. J. Haematol. Suppl. 66, 90-97 (2005).
68. Forrest DL, Hogge DE, Nevill TJ et al. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. J. Clin. Oncol, 23, 7994-8002 (2005).
69. Deeg HJ, Socie G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood 91, 1833-1844 (1998).
70. Krishnan A, Bhatia S, Slovak ML et al. Predictors of therapy-related leukaemia and myelodysplasia following autologous transplantation for lymphoma: as assessment of risk factors. Blood 95, 1588-1593 (2000).
71. Metayer C, Curtis RE, Vose J et al. Myelodysplastic syndrome and acute myeloid leukaemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 101, 2015-2023 (2003).
72. Dores GM, Metayer C, Curtis RE et al. Second malignant neoplasms among long-term survivors of Hogkin's disease: a population-based evaluation over 25 years. J. Clin. Oncol. 20, 3484-3494 (2002).
73. Van Leeuwen FE, Klokman WJ, Veer MB et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin. Oncol. 18, 487-497 (2000).
74. Andre M, Henry-Amar M, Blaise D et al. Treatment-related deaths and second cancer risk after autologous stem cell transplantation for Hodgkin's disease. Blood 92, 1933-1940 (1998).
75. Lavoie JC, Connors JM, Phillips GL et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 106, 1473-1478 (2005).
76. Chopra R, McMillan AK, Linch DC et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor risk Hodgkin's disease: a single-center eight-year study of 155 patients. Blood 81, 1137-1145 (1993).
77. Le Blanc K, Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 11, 321-334 (2005).
78. Schnell R, Dietlein M, Staak OJ et al. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J. Clin. Oncol. 23, 4669-4678 (2005).
79. + Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 101, 420-424 (2003).
80. Younes A, Romaguera J, Hagemeister et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 98, 310-314 (2003).